Trial Profile

A Phase I/IIa Clinical Trial to Evaluate the Safety,Tolerability,Pharmacokinetics and Preliminary Effectiveness of IAE0972 in Patients With Advanced Malignant Solid Tumors.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IAE 0972 (Primary)
Indications Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors SUNHO (China) BioPharmaceutical

Most Recent Events

21 Jul 2023 Results presented in the SUNHO (China) BioPharmaceutical media release Media Release.
21 Jul 2023 According to a SUNHO (China) BioPharmaceutical media release, drug received .S. Food and Drug Administration ("FDA") and National Medical Products Administration of People's Republic of China ("NMPA") investigational new drug ("IND") clearance and expects to initiate phase 2 trial soon.
07 Jun 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com